Statement: all participants in cohort 1 of the primary clinical trial survived, while cohort 2 had a mortality rate of 5%.
Primary_evidence: Outcome Measurement:    Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence)   Number of patients event-free   Time frame: 12 month period following randomisation Results 1:    Arm/Group Title: Fulvestrant + Anastrozole   Arm/Group Description: fulvestrant 500 mg + anastrozole 1 mg   Overall Number of Participants Analyzed: 6   Measure Type: Number   Unit of Measure: Participants  6 Results 2:    Arm/Group Title: Anastrozole   Arm/Group Description: anastrozole 1 mg   Overall Number of Participants Analyzed: 7   Measure Type: Number   Unit of Measure: Participants  7